The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
'AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines.'
Under this scholarship, first-year MBBS students from government colleges are eligible to receive monetary assistance of up to Rs 1,00,000 per year for a duration of up to 4.5 years, covering academic expenses incurred towards their MBBS degree.
Leading FMCG maker HUL said that it has received a demand notice of Rs 962.75 crore from the Income Tax Department and will go in for an appeal against the order. The notice relates to non-deduction of TDS on payment of Rs 3,045 crore to GlaxoSmithKline Consumer Healthcare (GSKCH) for the acquisition of Intellectual Property Rights of the Health Foods Drinks (HFD) business consisting of brands as Horlicks, Boost, Maltova, and Viva, according to a recent exchange filing.
After flirting with 'indulgent' variants, Horlicks and Foodles have tasted success with their health and nutrition positioning.
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
GlaxoSmithKline has filed a lawsuit in a United States court against Dr Reddy's Laboratories alleging infringement of patent rights of a generic version of 'Imitrex' drug, used for the treatment of migraine.
For instance, two of GSKCH's OTC products -- Eno and Iodex -- command a household penetration of 9 and 10 per cent respectively in metro cities. GSKCH has already drafted a channel strategy for modern trade in collaboration with South African retailer Shoprite, where cross-category and checkout placements were identified as an opportunity to create a shopping occasion through impulse buying.
The Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per cent shares in existing Indian subsidiary company of GSK Group.
The transaction is an all equity merger with 4.39 shares of HUL being allotted for every share in GlaxoSmithKline Consumer Healthcare India
A meeting of the board of directors of GlaxoSmithkline Consumer Healthcare Ltd is scheduled on January 31, 2003, inter alia, to consider and adopt the audited financial results for the year ended December 31, 2002.\n\n\n\n
GlaxoSmithkline Pharmaceuticals has posted a 52 per cent increase in net profit to Rs 35.09 crore for the first quarter ended March 31, 2003 as against Rs 23.02 crore for the corresponding quarter ended last fiscal.
The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.
Leading FMCG firm HUL on Thursday said it has switched to green fuel alternatives such as biomass and biodiesel and has eliminated the usage of coal across its operations. The company has collaborated with biomass suppliers and local farmers to ensure sustainable supply of green fuel and has made the necessary changes for the renewable transition in its coal-fired boilers, said an HUL statement. Besides, the shift from coal to renewable energy sources has also resulted in savings for the company, it added.
The company is increasing its exposure to key emerging markets.
The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.
Post the offer, GSK's holding will be 75 per cent from the present 43.2 per cent.
UK-headquartered consumer goods giant Unilever on Tuesday announced a major organisational shakeup to make the company leaner, which involves some of its Indian-origin executives, and plans to lay off 1,500 staff as part of the wider restructuring of its global operations. Sanjiv Mehta retains executive leadership of Mumbai-headquartered subsidiary Hindustan Unilever, while Unilever chief operating officer (COO) Nitin Paranjpe will take on a new role as chief transformation officer & chief people officer, leading the business transformation and heading the HR function for the transformed organisation. The company said Sunny Jain, president of beauty & personal care, has decided to leave Unilever to set up an "investment fund in technology megatrends".
The British pharma and consumer products maker had announced the open offer in November last year to raise its stake in its subsidiary to 75 per cent from 43.16 per cent at present.
Open offer to increase holding to 75%, fails to enthuse institutional investors.
According to the sources, the vaccine will be much more affordable than existing ones manufactured by two foreign companies. India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm.
Advertising on television continued to show momentum in May despite the surge in Covid-19 infections and the temporary suspension of the Indian Premier League (IPL), a high-impact television property. The data shared by the Broadcast Audience Research Council of India (BARC) on Thursday shows that advertising volumes in May were up 64 per cent year-on-year. However, there was a marginal dip sequentially, that is, in comparison to April 2021, when advertising had touched a record high owing to the start of the summer season and the return of the IPL to India after being held in the United Arab Emirates in 2020.
"We have a cash balance of close to Rs 1,500 crore. A majority of this balance can be used for acquisitions as our annual working capital requirement is only Rs 25-30 crore. I will not rule out a buyout of companies to expand our domestic business," said Mernosh Kapadia, senior executive director, GSK India. It is speculated that GlaxoSmithKline Plc is in talks to acquire leading Indian drug major Piramal Healthcare, in a deal valued over $1.5 billion.
The new malaria vaccine (RTS.S/ AS01, tentatively brand-named Mosquirix) is the very first one to offer immunity against a parasite -- specifically the plasmodium falciparum parasite, which is the deadliest of the five parasites that cause malaria.
Following its tie-up with Ranbaxy, pharma major GlaxoSmithKline said on Friday it was open to partnership with other Indian companies in the field of drug discovery and development, but it must be allowed to import molecules for research.
This is the third time in four years that the country's largest milk food drink is being relaunched.
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had filed an application with the US Food and Drug Administration to market a generic form of GlaxoSmithKline's anti-nausea drug Zofran.\n\n
After a strict lockdown impacting sales, India has returned to the growth path again, Anglo-Dutch FMCG major Unilever has said. The return of growth of India business, along with Brazil and continued recovery in China, helped the company's emerging markets clock a growth of 5.3 per cent in the September 2020 quarter.
Food regulator has closed more than 15 files.
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
However, foreign investors have completely shunned the infrastructure sector.
GSKAP takes care of all non-nutrition products whereas GSK Consumer Healthcare is a listed entity which deals only in nutritional products.
The sensitivity segment has quadrupled in the past two years, due to the aggressive marketing effort of both GSK and Colgate.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances